Trial Profile

Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractoy Mantle Cell Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary)
Indications Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms Ofatumumab Study

Most Recent Events

17 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
04 Dec 2011 United Kingdom Clinical Research Network reports accrual to date changed from 32 to 35%.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com